SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: hoffy who wrote (24964)12/9/1998 4:44:00 PM
From: NASDBULL  Read Replies (2) of 119973
 
ASTM will do VERY well tomorrow!!!!

The big difference between GERN and ASTM is that GERN's ownership in the stem cell finding was overlooked in the coverage because of the news focus on John Hopkins University and University of Wisconsin.

ASTM will likely get some direct exposure because they are pretty much the only ones involved. Am i correct in assuming this?

NASDBULL

Read the bold!!

Like bone marrow, umbilical cord blood contains the ''mother cells'' that can endlessly produce the cells that the body
needs to fight disease, Stiff said. But cord blood cells have the advantage of being ''immunologically naive,'' making
them more acceptable to the body and therefore not requiring a perfect donor match that is difficult to find.

''With our ability to expand cord blood cells, not only might most patients have a donor somewhere in the world, but
mortality rates may drop significantly -- a real breakthrough,'' Stiff said in a statement released by Loyola.

In the process developed by Ann Arbor, Michigan-based Aastrom Biosciences Inc (Nasdaq:ASTM - news)., the cells
are placed in a bioreactor -- an apparatus used to grow useful substances from living organisms -- then fed nutrients and
put in an incubator.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext